Home/Filings/4/0001209191-23-020682
4//SEC Filing

WILSON ROBERT N 4

Accession 0001209191-23-020682

CIK 0001534133other

Filed

Mar 21, 8:00 PM ET

Accepted

Mar 22, 8:52 PM ET

Size

22.8 KB

Accession

0001209191-23-020682

Insider Transaction Report

Form 4
Period: 2023-03-20
Transactions
  • Award

    Warrant

    2023-03-20+8,5928,592 total
    Exercise: $27.94Exp: 2026-06-25Common Stock (8,592 underlying)
  • Award

    Common Stock

    2023-03-20+181,655181,655 total
  • Award

    Director Stock Option (right to buy)

    2023-03-20+23,55723,557 total
    Exercise: $6.60Exp: 2030-06-29Common Stock (23,557 underlying)
  • Award

    Director Stock Option (right to buy)

    2023-03-20+5,7605,760 total
    Exercise: $7.99Exp: 2031-04-27Common Stock (5,760 underlying)
  • Award

    Director Stock Option (right to buy)

    2023-03-20+5,7605,760 total
    Exercise: $7.99Exp: 2031-06-30Common Stock (5,760 underlying)
  • Award

    Director Stock Option (right to buy)

    2023-03-20+7,5777,577 total
    Exercise: $17.34Exp: 2033-03-19Common Stock (7,577 underlying)
  • Award

    Director Stock Option (right to buy)

    2023-03-20+1,4881,488 total
    Exercise: $17.34Exp: 2033-03-19Common Stock (1,488 underlying)
  • Award

    Warrant

    2023-03-20+8,5928,592 total
    Exercise: $27.94Exp: 2026-02-22Common Stock (8,592 underlying)
Footnotes (11)
  • [F1]Received in exchange for 6,307,451 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc.
  • [F10]Immediately exercisable.
  • [F11]Received in exchange for a warrant to purchase 298,321 shares of common stock of CalciMedica pursuant to the Merger Agreement.
  • [F2]Beginning on June 15, 2020, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.
  • [F3]Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.
  • [F4]Received in exchange for a stock option to acquire 817,964 shares of common stock of CalciMedica pursuant to the Merger Agreement.
  • [F5]Beginning on November 22, 2022, the shares subject to the option vest in a series of twelve (12) successive equal monthly installments.
  • [F6]Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.
  • [F7]Received in exchange for a stock option to acquire 200,000 shares of common stock of CalciMedica pursuant to the Merger Agreement.
  • [F8]Received in exchange for a stock option to acquire 263,107 shares of common stock of CalciMedica pursuant to the Merger Agreement.
  • [F9]Received in exchange for a stock option to acquire 51,692 shares of common stock of CalciMedica pursuant to the Merger Agreement.

Issuer

CalciMedica, Inc. /DE/

CIK 0001534133

Entity typeother

Related Parties

1
  • filerCIK 0001189022

Filing Metadata

Form type
4
Filed
Mar 21, 8:00 PM ET
Accepted
Mar 22, 8:52 PM ET
Size
22.8 KB